- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03487406
Anti-platelet Therapy in the Prevention of Cardiovascular Disease in Patients With COPD (APPLE-COPD: ICON 2)
Anti-platelet Therapy in the Primary Prevention of Cardiovascular Disease in Patients With Chronic Obstructive Pulmonary Disease
Patients with COPD (chronic bronchitis and/or emphysema) are known to be at an increased risk of heart disease and death due to heart attacks. There are several possible reasons for this, one of which is an increased tendency of the blood to clot, that can give rise to blood clot formation in the coronary arteries, and lead to heart attack. Medications such as Aspirin and another new blood thinning tablet called Ticagrelor are already used for patients with heart attacks. Given that patients with COPD are at higher risk of heart attack, the investigators wish to see if these tablets that can prevent blood clot formation in heart arteries might also prevent heart attacks happening in COPD patients. The investigators hope to understand the effects by measuring clotting and inflammation in the blood. All patients will be followed up for 6-months.
In addition the investigators wish to study COPD patients who do not have a high risk of developing future heart problems using the QRISK score to study their well being over a 1 year period to see if they might also benefit from blood thinning medications.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The APPLE-COPD: ICON2 trial is a double blinded, proof-of-concept, randomised controlled trial that will include patients who have not been previously targeted in clinical cardiovascular research. The study will consist of patients with a lung condition called chronic obstructive pulmonary disease (COPD) who have not previously been diagnosed with coronary artery disease (CAD) and yet are at higher risk of CAD, myocardial infarction, and excess mortality (as determined by QRISK2 score). The QRISK2 is a simple questionnaire for heart disease that uses well known risk factors such as age, high blood pressure, smoking status and abnormal cholesterol levels. A QRISK score over 20 (20% risk of a cardiovascular event over the next ten years) is already used as a prompt to consider cholesterol lowering therapy (such as statins).
Patients with COPD (chronic bronchitis and/or emphysema) are known to be at an increased risk of heart disease and death due to heart attacks. There are several possible reasons for this, one of which is an increased tendency of the blood to clot which can give rise to blood clot formation in the coronary arteries, and lead to heart attack. Medications such as Aspirin and another new blood thinning tablet called Ticagrelor are already used for patients with heart attacks. Given that patients with COPD are at higher risk of heart attack, the investigators wish to see if these tablets that can prevent blood clot formation in heart arteries, might also prevent heart attacks happening in COPD patients. The investigators hope to understand the effects by measuring clotting and inflammation in the blood.
Aspirin and Ticagrelor are widely used in the UK for the management of coronary artery disease. For purposes of this study, Aspirin and Ticagrelor will be treated as an Investigational Medicinal Product (IMP). As a 2x2 factorial design, the primary analyses are based on a comparison of i) Aspirin vs no Aspirin and ii) Ticagrelor vs. no Ticagrelor (resulting in 4 treatment arms). Treatment allocation will be blinded to both the investigator and the participant.
Participants allocated to the treatment arms will be requested to take their trial medication for 6 months and will then be followed up clinically for a further 6 months by the research team to monitor any adverse events and the participant's well-being.
Participants allocated to the observational arm will be followed up for 1 year.
At 1 year all trial procedures will end and the patient will continue to receive routine care by the clinical care team.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Newcastle upon Tyne, United Kingdom, NE7 7DN
- Newcastle Upon Tyne Hospitals NHS Foundation Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Abnormal spirometry with FEV1<80% and FEV1/FVC ratio <70% of predicted
- Smoking history that is 10-pack years or greater (current or ex smokers can be included)
- Have capacity to consent
Exclusion Criteria:
- Any condition that is being concurrently treated through anticoagulation or antiplatelet therapy including Aspirin (any form of Aspirin) or Ticagrelor (atrial fibrillation, deep vein thrombosis, valve prosthesis, recent myocardial infarction, use of drug eluting stents)
- Other specific contraindications to management with antiplatelet medication (bleeding risks, allergies)
- Any contraindication for Aspirin and Ticagrelor use
- Other concurrent terminal illnesses with life expectancy less than 1 year (congestive cardiac failure, carcinoma etc)
- Current involvement in another clinical trial or exposure to another IMP within the previous 30 days
- COPD with an atypical cause (e.g. A1- antitrypsin deficiency)
- Patients who are unable to provide informed consent
- Planned/ Expected major surgery where anti-platelet therapy would be ceased
- Pregnancy, planned pregnancy or current breast-feeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo Ticagrelor & placebo Aspirin
Placebo Ticagrelor 90 mg- one tablet, twice daily.
Placebo Aspirin 75 mg- one tablet, once a day.
|
Sugar tablet to mimic Aspirin 75 mg tablet One 75 mg tablet, oral, once a day, for 6 months.
Sugar tablet to mimic Ticagrelor 90 mg tablet.
Once 90 mg tablet, oral, twice daily for 6 months.
|
Active Comparator: Aspirin & Placebo Ticagrelor
Aspirin 75mg - one tablet, once a day.
Placebo Ticagrelor 90 mg- one tablet, twice daily.
|
Sugar tablet to mimic Ticagrelor 90 mg tablet.
Once 90 mg tablet, oral, twice daily for 6 months.
One 75 mg tablet, oral, once a day, for 6 months.
|
Active Comparator: Placebo Aspirin & Ticagrelor
Placebo Aspirin 75 mg - one tablet, once a day.
Ticagrelor 90 mg- one tablet, twice daily.
|
Sugar tablet to mimic Aspirin 75 mg tablet One 75 mg tablet, oral, once a day, for 6 months.
One 90 mg tablet, oral, twice daily for 6 months.
Other Names:
|
Experimental: Aspirin & Ticagrelor
Aspirin 75 mg - one tablet, once a day.
Ticagrelor 90 mg- one tablet, twice daily.
|
One 75 mg tablet, oral, once a day, for 6 months.
One 90 mg tablet, oral, twice daily for 6 months.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in baseline ASPI and ADP-induced platelet aggregation at 6 months
Time Frame: Baseline to 6 months
|
The primary outcome measure is platelet reactivity measured at 6-months. Response is calculated according to high platelet reactivity (HPR). Rates of HPR will be determined according to recently published definitions of HPR for multiple electrode aggregometry in patients undergoing percutaneous coronary intervention, >46 AU for ADP test and >40 for ASPI test. Response rate will be calculated on an intention to treat basis as the total number of patients responding as a proportion of all patients randomised and reported descriptively with 95% confidence intervals. Any patients who are not assessable at 6-months will be classed as a non-responder. |
Baseline to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in inflammatory markers (myeloperoxidase (MPO) measured by routine blood test at baseline, 1 month and 6 months
Time Frame: Baseline to 6 months
|
Measuring changes in inflammatory markers to investigate if treatment with APT is associated with reduced inflammatory marker levels (myeloperoxidase (MPO)).
|
Baseline to 6 months
|
Change in inflammatory markers (interleukin-6 (IL-6) measured by routine blood test at baseline, 1 month and 6 months
Time Frame: Baseline to 6 months
|
Measuring changes in inflammatory markers to investigate if treatment with APT is associated with reduced inflammatory marker levels (interleukin-6 (IL-6)).
|
Baseline to 6 months
|
Change in inflammatory markers (fibrinogen) measured by routine blood test at baseline, 1 month and 6 months
Time Frame: Baseline to 6 months
|
Measuring changes in inflammatory markers to investigate if treatment with APT is associated with reduced inflammatory marker levels (fibrinogen).
|
Baseline to 6 months
|
Change in inflammatory markers (high sensitive C reactive protein (hsCRP) measured by routine blood test at baseline, 1 month and 6 months
Time Frame: Baseline to 6 months
|
Measuring changes in inflammatory markers to investigate if treatment with APT is associated with reduced inflammatory marker levels (high sensitive C reactive protein (hsCRP)).
|
Baseline to 6 months
|
Change in inflammatory markers (tumor necrosis factor alpha (TNF) measured by routine blood test at baseline, 1 month and 6 months
Time Frame: Baseline to 6 months
|
Measuring changes in inflammatory markers to investigate if treatment with APT is associated with reduced inflammatory marker levels (tumor necrosis factor alpha (TNF)).
|
Baseline to 6 months
|
Changes in carotid intima media thickness
Time Frame: Baseline to 6 months
|
Carotid intima media thickness measured by an ultrasound scan
|
Baseline to 6 months
|
Changes in vascular stiffness (m/s)
Time Frame: Baseline and 6-months
|
Changes in vascular stiffness as measured by a cuff (Meter/Second)
|
Baseline and 6-months
|
Quality of life using EuroQoL-5D-5L health-related quality of life instrument
Time Frame: Baseline and 6-months
|
The EQ-5D-5L consists of the EQ-5D-5L descriptive system and the EQ Visual Analogue scale (EQ VAS).
The descriptive system has 5 dimensions (mobility, self care, usual activities, pain/discomfort, anxiety/depression), each with 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems.
The respondent indicates his/her health state in each of the 5 dimensions.
This decision results in a 1-digit number expressing the level selected for that dimension.
The digits for 5 dimensions can be combined in a 5-digit number describing the respondent's health state.
The EQ Visual Analogue Scale records the respondent's self-rated health on a vertical, visual analogue scale (0-100) where the endpoints are labelled 'Best imaginable health state' (100) and 'Worst imaginable health state' (0).
This information will be used as a quantitative measure of health outcome as judged by the individual respondents.
|
Baseline and 6-months
|
St George's Respiratory Questionnaire for Chronic Obstructive Pulmonary Disease Patients (SGRQ-C)
Time Frame: Baseline and 6-months
|
The SGRQ measures health impairment in patients with asthma and COPD.
Scored 0-100 (with 0 = best outcome and 100 worst outcome)
|
Baseline and 6-months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rates of major and minor bleeding as defined by the TIMI scale
Time Frame: Baseline to 6 months
|
Rates of bleeding will be classified as per the TIMI Scale: Major - Intracranial haemorrhage or a ≥5 g/dl decrease in the haemoglobin concentration or a ≥15% absolute decrease in the haematocrit Minor- Observed blood loss: ≥3 g/dl decrease in the haemoglobin concentration or ≥10% decrease in the haematocrit Minor- No observed blood loss: ≥4 g/dl decrease in the haemoglobin concentration or ≥12% decrease in the haematocrit Minimal- Any clinically overt sign of haemorrhage (including imaging) that is associated with a <3 g/dl decrease in the haemoglobin concentration or <9% decrease in the haematocrit All Adverse Events (AE) will be reported descriptively as the number of patients experiencing an AE as a proportion of the total number of patients starting treatment. |
Baseline to 6 months
|
Rates of major and minor bleeding as defined by the Bleeding Academic Research Consortium (BARC) definition.
Time Frame: Baseline to 6 months
|
Rates of bleeding will be defined by bleeding type i.e.
Type 0 -Type 5b
|
Baseline to 6 months
|
Response on spirometry using the MRC dyspnoea scale (Breathlessness)
Time Frame: Baseline to 6 months
|
Spirometry will be measured using the MRC Breathlessness Scale-
|
Baseline to 6 months
|
Forced Expiratory Volume (FEV1) and Forced Vital Capacity (FVC) measured by spirometry
Time Frame: Baseline to 6 months
|
A spirometer will be used to measure Forced Expiratory Volume (FEV1) and Forced Vital Capacity (FVC).
|
Baseline to 6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Vijay Kunadian, MBBS MD FRCP, Intitute of Cellular Medicine, Newcastle University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Cardiovascular Diseases
- Lung Diseases
- Lung Diseases, Obstructive
- Pulmonary Disease, Chronic Obstructive
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
- Purinergic P2Y Receptor Antagonists
- Purinergic P2 Receptor Antagonists
- Purinergic Antagonists
- Purinergic Agents
- Aspirin
- Ticagrelor
Other Study ID Numbers
- 2014-005475-86
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease (COPD)
-
University College, LondonUniversity of Cambridge; National Institute for Health Research, United Kingdom and other collaboratorsUnknownChronic Obstructive Pulmonary Disease (COPD).United Kingdom
-
Virginia Commonwealth UniversityFisher and Paykel HealthcareCompletedChronic Obstructive Pulmonary Disease(COPD)United States
-
Reham Mohammed ElmorshedyCompletedChronic Obstructive Pulmonary Disease(COPD)Egypt
-
AstraZenecaCompletedChronic Obstructive Pulmonary Disease (COPD).United Kingdom
-
Medtronic BRCUnknownCOPD | COPD Exacerbation
-
Beaumont HospitalAerogenCompletedChronic Obstructive Pulmonary Disease | COPD | COPD Exacerbation | Copd Exacerbation AcuteIreland
-
Chiesi Farmaceutici S.p.A.CompletedModerate to Severe Chronic Obstructive Pulmonary Disease (COPD)Bulgaria, Germany, Hungary, Poland, Russian Federation, United Kingdom
-
Chiesi Farmaceutici S.p.A.CompletedChronic Obstructive Pulmonary Disease (COPD) | COPDUnited Kingdom
-
Elpen Pharmaceutical Co. Inc.Completed
-
Aalborg UniversityCompletedChronic Obstructive Pulmonary Disease | COPD | COPD Exacerbation | COPD Exacerbation AcuteDenmark
Clinical Trials on Placebo Aspirin
-
Queen Mary University of LondonCancer Research UK; Barts and the London School of Medicine and DentistryCompletedProstate CancerUnited Kingdom
-
Seoul National University HospitalCKD Pharmaceutical LimitedCompleted
-
Woo Hyun PaikTerminatedBiliary Stasis, ExtrahepaticKorea, Republic of
-
University College, LondonRecruitingCancer | Breast Cancer | Colorectal Cancer | Prostate Cancer | Gastro-oesophageal CancerIreland, United Kingdom
-
Dave HostlerFederal Emergency Management Administration; Eyemarker Systems, IncCompletedHeat Stress DisordersUnited States
-
Columbia UniversityNational Institute of Neurological Disorders and Stroke (NINDS)Completed
-
The First Affiliated Hospital with Nanjing Medical...UnknownCoronary AtherosclerosisChina
-
Oxford University Clinical Research Unit, VietnamHospital for Tropical Diseases, Ho Chi Minh City, VietnamCompletedTuberculous MeningitisVietnam
-
National Institute of Diabetes and Digestive and...Boston University; Washington University School of Medicine; University of Alabama... and other collaboratorsCompleted